Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genzyme's Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design

Published: Friday, April 20, 2012
Last Updated: Friday, April 20, 2012
Bookmark and Share
Site is Genzyme's tenth LEED-certified Green Building.

Genzyme, a Sanofi company , today announced that its Biologics Support Center in Framingham, Mass., received a Gold certification under the U.S. Green Building Council's LEED(R) (Leadership in Energy and Environmental Design) Green Building Rating System(TM). This is the tenth Genzyme building to achieve a LEED rating for sustainable construction and design.

The Framingham Biologics Support Center is an administrative and lab building connected to Genzyme's newly approved manufacturing facility that produces Fabrazyme(R) (agalsidase beta). The 186,000 square foot facility accommodates approximately 550 employees, including manufacturing, support, and administrative staff for the manufacturing plant.

"The achievement of ten LEED certifications demonstrates Genzyme's ongoing dedication to pursuing and meeting high standards in every aspect of our business," said Genzyme's President and CEO David Meeker. "We are committed to being a responsible corporate citizen and a good neighbor in our communities."

Biologics Support Center Features

LEED certification provides independent, third-party verification that a building was designed and built using strategies aimed at achieving high performance in five key areas of human and environmental health: energy efficiency, water savings, materials selection, sustainable site development, and indoor environmental quality. The Framingham Biologics Support Center was designed to achieve goals in each of these areas.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme, Ablynx Launch MS Collaboration
Genzyme has agreed to use Ablynx's therapeutic proteins to carry out in vitro and in vivo research on multiple sclerosis models, then develop therapies against the disease.
Tuesday, May 19, 2015
Genzyme Receives Company Award
Genzyme, announced that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases.
Thursday, February 28, 2013
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!